iVeena Delivery Systems, Inc., founded with a mission to innovate ocular drug solutions, focuses on developing non-surgical, non-invasive pharmacologic treatments for significant unmet medical needs such as keratoconus, progressive myopia, and cystoid macular edema. The company leverages two platform technologies: topical delivery of copper for corneal conditions and drug delivery from the lens capsule for cataract-related issues. iVeena aims to transform the treatment landscape for these eye diseases through its clinical-stage developments.
Notable affiliated individuals include experts in ophthalmology and pharmacology, contributing to the company's robust research and development efforts. iVeena has garnered attention and investment from key players in the biotech and medical fields, underscoring its potential impact. The company's innovative approaches have positioned it as a promising leader in ocular therapeutics, with the potential to significantly improve patient outcomes in the ophthalmology sector.
